Be aware of (R)-methamphetamine : Negative immunoassay versus positive confirmation analysis
© 2023 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd..
The amphetamine-type stimulant methamphetamine exists in two enantiomeric forms, (S)-methamphetamine and (R)-methamphetamine, which are both psychoactive but with the (S)-enantiomer being more potent than the (R)-enantiomer. Illicit methamphetamine encountered in Europe is typically a racemic mixture of both enantiomers and enantiopure (S)-methamphetamine, respectively. However, herein we report two cases with proven enantiopure (R)-methamphetamine consumption with moreover both cases remaining undetected by immunoassay screening. Inconspicuous immunoassay findings can be traced back to a considerably higher sensitivity and concentration-dependent cross-reactivity of the applied drug of abuse assay for the (S)-enantiomer of methamphetamine compared with the (R)-enantiomer, and this limitation should be well known by users of immunoassay drug tests.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Drug testing and analysis - 16(2024), 4 vom: 17. Apr., Seite 392-397 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liut, Jennifer [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
(R)‐methamphetamine |
|---|
| Anmerkungen: |
Date Completed 04.04.2024 Date Revised 04.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/dta.3556 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360015026 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360015026 | ||
| 003 | DE-627 | ||
| 005 | 20240404234235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/dta.3556 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM360015026 | ||
| 035 | |a (NLM)37501581 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liut, Jennifer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Be aware of (R)-methamphetamine |b Negative immunoassay versus positive confirmation analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd. | ||
| 520 | |a The amphetamine-type stimulant methamphetamine exists in two enantiomeric forms, (S)-methamphetamine and (R)-methamphetamine, which are both psychoactive but with the (S)-enantiomer being more potent than the (R)-enantiomer. Illicit methamphetamine encountered in Europe is typically a racemic mixture of both enantiomers and enantiopure (S)-methamphetamine, respectively. However, herein we report two cases with proven enantiopure (R)-methamphetamine consumption with moreover both cases remaining undetected by immunoassay screening. Inconspicuous immunoassay findings can be traced back to a considerably higher sensitivity and concentration-dependent cross-reactivity of the applied drug of abuse assay for the (S)-enantiomer of methamphetamine compared with the (R)-enantiomer, and this limitation should be well known by users of immunoassay drug tests | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a (R)‐methamphetamine | |
| 650 | 4 | |a cross‐reactivity | |
| 650 | 4 | |a enantioselective analysis | |
| 650 | 4 | |a immunoassay drug test | |
| 650 | 7 | |a Methamphetamine |2 NLM | |
| 650 | 7 | |a 44RAL3456C |2 NLM | |
| 650 | 7 | |a Amphetamine |2 NLM | |
| 650 | 7 | |a CK833KGX7E |2 NLM | |
| 700 | 1 | |a Madea, Burkhard |e verfasserin |4 aut | |
| 700 | 1 | |a Krämer, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Maas-Gramlich, Alexandra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug testing and analysis |d 2009 |g 16(2024), 4 vom: 17. Apr., Seite 392-397 |w (DE-627)NLM196999022 |x 1942-7611 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:4 |g day:17 |g month:04 |g pages:392-397 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/dta.3556 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 4 |b 17 |c 04 |h 392-397 | ||